Alternatives to Foresee Genomics

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Variantyx is a precision medicine company offering comprehensive genomic testing solutions for rare genetic disorders, reproductive health, and oncology.

AI-powered spatial biology platform for precision medicine and drug development.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Precision oncology company developing cancer therapies guided by proprietary functional genomics.

Nucleix is a liquid biopsy company developing early cancer detection solutions using methylation analysis.

Biotech company using AI and deep RNA analysis to predict cancer treatment response.

Harnessing genetic data for digital insights in rare and germline disorders.

Developing a liquid biopsy blood test for early disease detection and monitoring using epigenetic information.

Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.

Developing novel diagnostics to predict patient response to immunotherapy.

Develops a computational model of the human body for drug discovery and development.

AI-powered multi-omics platform for early breast cancer detection and risk prediction.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science.

Comprehensive whole-genome monitoring for cancer recurrence and progression.

Genoox provides a cloud-based AI platform for genomic data analysis, connecting clinicians and healthcare organizations.

MeMed develops and commercializes host immune response diagnostic solutions to address complex clinical dilemmas and improve patient outcomes.

Pioneering volatile markers (VM) tests for early cancer detection in large-scale populations.